Table 1.
Treatment arms | Systemic therapies given concomitantly | Phase | No. | ORR, % | PFS |
OS |
Reference | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Median, mo | HR | P | Median, mo | HR | P | |||||||
Cetuximab | Cisplatin | — | III | 57 | 26 | 4.2 | 0.78 | NS | 9.2 | NA | — | (21) |
Cisplatin | — | 60 | 10 | 2.7 | 8 | |||||||
Cetuximab | Platinum | 5FU | III | 222 | 36 | 5.6 | 0.54 | <.001 | 10.1 | 0.9 | .04 | (5) |
Platinum | 5FU | 220 | 20 | 3.3 | 7.4 | |||||||
Panitumumab | Cisplatin | 5FU | III | 327 | 37 | 5.8 | 0.78 | .004 | 11.1 | 0.87 | NS | (22) |
Cisplatin | 5FU | 330 | 26 | 4.6 | 9 | |||||||
Panitumumab | Cisplatin | Docetaxel | II | 56 | 44 | 6.9 | 0.63 | .048 | 12.9 | 1.1 | — | (23) |
Cisplatin | Docetaxel | 57 | 37 | 5.5 | 13.8 | NA | ||||||
Zalutumumab | — | — | III | 191 | 6 | 2.2 | 0.63 | .001 | 6.7 | 0.77 | NS | (24) |
BSC | — | — | 95 | 1 | 1.9 | 5.2 | ||||||
Gefitinib | Docetaxel | — | III | 134 | 12.5 | 3.5 | 0.81 | NS | 7.3 | 0.93 | NS | (25) |
Docetaxel | — | 136 | 6.2 | 2.1 | 6 | |||||||
Gefitinib 500 mg | — | — | III | 167 | 8 | NA | NA | — | 6 | 1.12 | — | (26) |
Gefitinib 250 mg | — | — | 158 | 3 | NA | NA | — | 5.6 | 1.22 | — | ||
Methotrexate | — | — | 161 | 4 | NA | NA | — | 6.7 | — | — | ||
Afatinib | — | — | III | 322 | 10 | 2.6 | 0.8 | .03 | 6.8 | 0.96 | NS | (27) |
Methotrexate | — | — | 161 | 6 | 1.7 | 6 | ||||||
Afatinib | — | — | II | 61 | 8 | 2.9 | 0.93 | NS | 8 | 1.06 | NS | (28) |
Cetuximab | — | — | 60 | 10 | 3.3 | 10.5 |
BSC = best supportive care; EGFR = epidermal growth factor receptor; 5FU = 5-fluorouracil; HNSCC = head and neck squamous cell carcinoma; HR = hazard ratio; NA = not available; NS = not statistically significant; ORR = objective response rate; OS = overall survival; PFS = progression-free survival.